AlphAIAlphAI — Financial news for AI agents
onclive.comSEP 302 min read$TEVA

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

Original reporting
onclive.com
Published Sep 30, 2026, 1:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy — source image
Source · onclive.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The approval adds a high-demand oncology and bone health product to Teva's pipeline, likely improving earnings outlook.

02

Market read

First FDA approval of this biosimilar provides a material catalyst for Teva's stock and the broader biosimilar market.

03

What to watch

Potential reimbursement challenges and competition from other denosumab biosimilars could temper revenue impact.

Relevance 9/10Novelty 9/10Timing: today

Background

Teva Pharmaceuticals announced FDA approval of its denosumab biosimilar, Degevma, expanding its biosimilar portfolio after earlier Prolia biosimilar approval.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approval of Teva's denosumab biosimilar (Degevma) for all indications, enabling US launch in coming months.

Expected impact

upward pressure as investors price in future sales and market share gains.

Evidence & confidence

First-time FDA approval of a biosimilar is material news; Teva's existing oncology pipeline and upcoming launch suggest revenue upside.

Market effects

Sector

Strengthens the US biosimilar and oncology drug sector, may spur competitive pricing.

Regional

US biotech and pharma markets see potential revenue uplift.

Global

Sets precedent for global biosimilar competition, could affect European and Asian markets.

Counterpoint

What could challenge this read

Market may have already priced in the approval; launch delays or pricing pressure could limit upside.

Key entities

  • Company
    Teva Pharmaceuticals

    US-listed pharmaceutical company receiving FDA approval for a denosumab biosimilar.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 29
$TEVAHighAI 9/10

FDA nod for Teva’s Degevma biosimilar

Teva Pharmaceutical Industries (TEVA) received FDA approval for Degevma, a biosimilar to Amgen's Xgeva (denosumab). Degevma is indicated for preventing bone complications in advanced cancer, treating giant cell tumors, and managing hypercalcemia of malignancy. This approval expands Teva's oncology portfolio.

thepharmaletter.com2 min
SEP 29
$TEVAHighAI 9/10

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Teva Pharmaceutical Industries received U.S. FDA approval for denosumab-adet, a biosimilar to denosumab, for all indications of the reference product. The approval expands Teva's biosimilar portfolio in oncology and bone health, offering a new treatment option. Denosumab-adet is approved for preventing skeletal-related events in advanced cancer, treating giant cell tumor of bone, and managing hypercalcemia of malignancy.

oncodaily.com2 min
SEP 29
$TEVAMedAI 8/10

Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva

Teva Pharmaceutical (TEVA) received FDA approval for DEGEVMA, a biosimilar to Xgeva. The approval is based on data showing comparable efficacy, safety, and immunogenicity. DEGEVMA is indicated for bone complications in cancer patients and other conditions. Teva plans to launch DEGEVMA and PONLIMSI in the U.S. soon. TEVA stock closed at $38.88, up 0.31% in after-hours trading.

rttnews.com1 min